Fred Alger Management, LLC Chemo Centryx, Inc. Transaction History

Fred Alger Management, LLC

$19.8 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $1.38 Million - $2.47 Million	-89,828 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $1.38 Million - $2.44 Million	-62,269 Reduced 40.94%	89,828 $2.25 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $2.8 Million - $6.16 Million	152,097 New	152,097 $5.54 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $1.15 Million - $1.59 Million	-23,235 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $24,759 - $34,143	-524 Reduced 2.21%	23,235 $1.44 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $289,270 - $385,007	-6,241 Reduced 20.8%	23,759 $1.3 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $327,299 - $507,800	10,000 Added 50.0%	30,000 $1.21 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $136,200 - $791,000	20,000 New	20,000 $791,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.